Table of Contents Author Guidelines Submit a Manuscript
Journal of Nanomaterials
Volume 2016, Article ID 3451685, 8 pages
http://dx.doi.org/10.1155/2016/3451685
Research Article

Delivery Efficiency of miR-21i-CPP-SWCNT and Its Inhibitory Effect on Fibrosis of the Renal Mesangial Cells

1Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, Southern Medical University, Guangdong, Guangzhou 510515, China
2Department of Nephrology, Third Affiliated Hospital, Southern Medical University, Guangzhou, Guangdong 510603, China
3Division of Nephrology, Nanfang Hospital, Southern Medical University, Key Lab for Organ Failure Research, Ministry of Education, Guangzhou, Guangdong 510515, China
4Department of Anatomy, Zhuhai School Campus of Zunyi Medical College, Zhuhai, Guangdong 519041, China

Received 13 September 2016; Accepted 30 October 2016

Academic Editor: Xiaolian Sun

Copyright © 2016 Hong Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. D. McClelland, M. Herman-Edelstein, R. Komers et al., “miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7,” Clinical Science, vol. 129, no. 12, pp. 1237–1249, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Y. Gu, H. Z. Li, L. Y. Chen et al., “MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis,” Oncotarget, vol. 6, no. 32, pp. 32545–32560, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Glowacki, G. Savary, V. Gnemmi et al., “Increased circulating miR-21 levels are associated with kidney fibrosis,” PLoS ONE, vol. 8, no. 2, Article ID e58014, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. I. G. Gomez, N. Nakagawa, and J. S. Duffield, “MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis,” American Journal of Physiology. Renal Physiology, vol. 310, no. 10, pp. P391–P944, 2016. View at Google Scholar
  5. J. Pahle and W. Walther, “Vectors and strategies for nonviral cancer gene therapy,” Expert Opinion on Biological Therapy, vol. 16, no. 4, pp. 443–461, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Nedaeinia, M. Sharifi, A. Avan et al., “Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach,” Cancer Gene Therapy, vol. 23, pp. 246–253, 2016. View at Publisher · View at Google Scholar
  7. P. Jolly, P. Estrela, and M. Ladomery, “Oligonucleotide-based systems: DNA, microRNAs, DNA/RNA aptamers,” Essays in Biochemistry, vol. 60, no. 1, pp. 27–35, 2016. View at Publisher · View at Google Scholar
  8. X. Jiang, G. Wang, R. Liu et al., “RNase non-sensitive and endocytosis independent siRNA delivery system: delivery of siRNA into tumor cells and high efficiency induction of apoptosis,” Nanoscale, vol. 5, no. 16, pp. 7256–7264, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Wang, T. Zhao, L. Wang et al., “Studying different binding and intracellular delivery efficiency of ssDNA single-walled carbon nanotubes and their effects on LC3-related autophagy in renal mesangial cells via miRNA-382,” ACS Applied Materials & Interfaces, vol. 7, pp. 25733–25740, 2015. View at Google Scholar
  10. M. P. Landry, L. Vuković, S. Kruss et al., “Comparative dynamics and sequence dependence of DNA and RNA binding to single walled carbon nanotubes,” The Journal of Physical Chemistry C: Nanomaterials and Interfaces, vol. 119, no. 18, pp. 10048–10058, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Giacomotto, S. Rinkwitz, and T. S. Becker, “Effective heritable gene knockdown in zebrafish using synthetic microRNAs,” Nature Communications, vol. 6, article 7378, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. Y.-J. Tao, Y.-J. Li, W. Zheng et al., “Antisense oligonucleotides against microRNA-21 reduced the proliferation and migration of human colon carcinoma cells,” Cancer Cell International, vol. 15, article 77, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. J. S. Suh, J. Y. Lee, Y. S. Choi, P. C. Chong, and Y. J. Park, “Peptide-mediated intracellular delivery of miRNA-29b for osteogenic stem cell differentiation,” Biomaterials, vol. 34, no. 17, pp. 4347–4359, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. Q. L. Hu, Q. Y. Jiang, X. Jin et al., “Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model,” Biomaterials, vol. 34, no. 9, pp. 2265–2276, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Yuan, Y. Lee, U. Choi, G. Moeckel, and A. Karihaloo, “Chemokine receptor Cxcr4 contributes to kidney fibrosis via multiple effectors,” American Journal of Physiology—Renal Physiology, vol. 308, no. 5, pp. F459–F472, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Liu, Y. Li, H. Wang et al., “BH3-based fusion artificial peptide induces apoptosis and targets human colon cancer,” Molecular Therapy, vol. 17, no. 9, pp. 1509–1516, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. Qian, A. Martyna, R. L. Hard et al., “Discovery and mechanism of highly efficient cyclic cell-penetrating peptides,” Biochemistry, vol. 55, no. 18, pp. 2601–2612, 2016. View at Publisher · View at Google Scholar
  18. R. Bijkerk, R. G. de Bruin, C. van Solingen et al., “Silencing of microRNA-132 reduces renal fibrosis by selectively inhibiting myofibroblast proliferation,” Kidney International, vol. 89, no. 6, pp. 1268–1280, 2016. View at Publisher · View at Google Scholar
  19. A. C. K. Chung, Y. Dong, W. Yang, X. Zhong, R. Li, and H. Y. Lan, “Smad7 suppresses renal fibrosis via altering expression of TGF-β/Smad3-regulated microRNAs,” Molecular Therapy, vol. 21, no. 2, pp. 388–398, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Y. Lan, “Transforming growth factor-β/Smad signalling in diabetic nephropathy,” Clinical and Experimental Pharmacology & Physiology, vol. 39, no. 8, pp. 731–738, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. X. Zhong, A. C. K. Chung, H.-Y. Chen, X.-M. Meng, and H. Y. Lan, “Smad3-mediated upregulation of miR-21 promotes renal fibrosis,” Journal of the American Society of Nephrology, vol. 22, no. 9, pp. 1668–1681, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. X.-M. Meng, P. M.-K. Tang, J. Li, and H. Y. Lan, “TGF-β/Smad signaling in renal fibrosis,” Frontiers in Physiology, vol. 6, article 82, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. R. J. Johnson, H. Iida, C. E. Alpers et al., “Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis: α-Smooth muscle actin is a marker of mesangial cell proliferation,” The Journal of Clinical Investigation, vol. 87, no. 3, pp. 847–858, 1991. View at Publisher · View at Google Scholar · View at Scopus